

# Pharmacogenomic Testing

Mental health is personal. Your treatment should be too.



## What Is Pharmacogenomic Testing (PGx)?

**Pharmacogenomics is the study of how your DNA may affect your response to medications.** This kind of testing uses information about a person's genetic makeup to help inform health care providers' medication selection and dosage.

**Pharmacogenomic tests provide genetic information that is unique to each patient.** For example, [research indicates](#) that genetic variations may explain up to 42% of the differences in how people respond to antidepressants.

It's important to remember that **lifestyle factors** like smoking and diet, and interactions with other medications, **can also impact treatment effectiveness.**

## Why PGx Matters for Mental Health

Finding the mental health medication that works best for you can often mean months of trial and error. [Less than 40% of people achieve remission](#) from depression on their first medication.



**Pharmacogenomic testing may help** when:

- You've tried mental health **medications that didn't work.**
- You've had **bad side effects.**
- **You haven't found relief** after multiple medication attempts.



In [a study of nearly 2,000 people](#) with a history of treatment for Major Depressive Disorder (MDD), those who underwent pharmacogenomic testing were **more likely to achieve remission** over 24 weeks of treatment compared to those who did not receive pharmacogenomic testing, and less likely to be prescribed medications with predicted gene-drug interactions.



Another [large study](#) showed **significantly reduced general and psychiatric hospitalizations** among people with MDD following pharmacogenomic testing, especially when patients were switched to medications with no or moderate gene-drug interactions.

# What the Test Looks For

## Two types of genetic clues:

### Pharmacodynamic factors (how your body reacts to medication)

- SLC6A4 gene: Can show if SSRIs may be less likely to work.
- HTR2A gene: Can signal the risk of side effects for certain SSRI medications.
- HLA-B\*1502 and HLA-A\*3101 genes: Can predict dangerous skin reactions for certain mood stabilizer medications.
- ADRA2A gene: Can help determine if certain stimulant medications may be less likely to work for you.

### Pharmacokinetic factors (how your body breaks down medication)

- Whether your body breaks down medications too fast or too slowly. This can help determine changes in the dose you may need, or if you should consider switching medications.
- The impact that smoking cigarettes or marijuana has on how your body processes certain medications.

## How Testing Works

- Testing is often considered after you've tried other medications.
- It must be ordered by a doctor or licensed provider.
- A cheek swab is taken and sent to a lab.
- Results are sent to your clinician to review with you.



[Click here](#) for tools to start a conversation

## Thinking About Getting Tested?

- **Keep notes** on what medications you've tried and how they worked
- **Talk to your mental health provider** about whether it's right for you – scan the QR code for tools to start a conversation
- **Ask your insurance** what's covered and what your costs might be
- **Financial assistance is available** for eligible patients to help cover out-of-pocket expenses

### Sources

- Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. *Biol Psychiatry*. 2013.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am J Psychiatry*. 2006.
- Oslin DW, Lynch KG, Shih M, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care trial. *JAMA*. 2022.
- Del Tredici AL, Johnson HL, DeHart B, et al. Real-world impact of pharmacogenomic testing on medication use and healthcare resource utilization in patients with major depressive disorder. *J Clin Psychopharmacol*. 2025.